{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:34:15Z","timestamp":1781224455828,"version":"3.54.1"},"reference-count":50,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:00:00Z","timestamp":1526428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>New drugs for treating hepatitis C have considerably increased the probability of being cured. Treatment uptake, however, is still low. The objectives of this study were to analyse the impact of initiatives that may increase the proportion of infected people on treatment and interventions aimed at reducing the incidence of new infection among people who inject drugs. A compartmental model for Norway was used to simulate hepatitis C and related complications. We analysed 2 different screening initiatives aimed to increase the proportion of infected people on treatment. Interventions aiming at reducing the hepatitis C incidence analysed were opioid substitution therapy (<jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content>), a clean needle and syringe programme and a combination of both. The most cost\u2010effective strategy for increasing hepatitis C treatment uptake was screening by general practitioners while simultaneously allowing for all infected people to be treated. We estimated that this intervention reduces the incidence of hepatitis C by 2030 by 63% compared with the current incidence. The 2 harm reduction strategies both reduced the incidence of hepatitis C by about 70%. Combining an increase in the current clean needles and syringe programme with <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content> was clearly the most cost\u2010effective option. This strategy would reduce the incidence of hepatitis C by 80% compared with the current incidence by 2030. Thus, interventions to reduce the burden and spread of hepatitis C are cost\u2010effective. Reaching the WHO target of a 90% reduction in hepatitis C incidence by 2030 may be difficult without combining different initiatives.<\/jats:p>","DOI":"10.1111\/jvh.12904","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T22:42:07Z","timestamp":1523054527000},"page":"1066-1077","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Feasibility of reaching world health organization targets for hepatitis C and the cost\u2010effectiveness of alternative strategies"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7539-082X","authenticated-orcid":false,"given":"T.","family":"Wisl\u00f8ff","sequence":"first","affiliation":[{"name":"Department of Infectious Disease Epidemiology and Modelling Norwegian Institute of Public Health  Oslo Norway"},{"name":"Department of Health Management and Health Economics University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology and Modelling Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Dalgard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Akershus University Hospital  L\u00f8renskog Norway"},{"name":"Division of Medicine and Laboratory Sciences University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Amundsen","sequence":"additional","affiliation":[{"name":"Department of Alcohol, Tobacco and Drugs Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Meijerink","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology and Modelling Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kl\u00f8vstad","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Blood Borne and Sexually Transmitted Infections Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2631-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0373-9"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.008"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28327"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.007"},{"key":"e_1_2_9_7_1","volume-title":"Drugs for Chronic Hepatitis C Infection: Cost\u2010Effectiveness Analysis","author":"Wong W","year":"2016"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12546"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1152"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13223"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0604-3"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.04.021"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166451"},{"key":"e_1_2_9_14_1","volume-title":"Mortality, Morbidity and Treatment Uptake Related to Hepatitis C Among People who Have Injected Drugs in Norway","author":"Kielland KB","year":"2015"},{"key":"e_1_2_9_15_1","volume-title":"Blood\u2010 and Sexually Transmitted Infections in Norway 2016","author":"Nilsen \u00d8","year":"2017"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058975"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25510"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-4-201202210-00378"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis011"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.140711"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26431"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27736"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0136-z"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X08315240"},{"key":"e_1_2_9_25_1","volume-title":"Hepatitis C \u2013 New Drugs Give Better Treatment Options","author":"Tollefsen KB","year":"2014"},{"key":"e_1_2_9_26_1","volume-title":"Performance\u2010Based Financing 2016","year":"2015"},{"key":"e_1_2_9_27_1","volume-title":"Normal Tariff for Contract Specialists 2015\u20132016"},{"key":"e_1_2_9_28_1","volume-title":"Hepatitis C Among Drug Users in Europe: Epidemiology, Treatment And Prevention","author":"Addiction EEMCfDaD","year":"2016"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03515.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.12.035"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9958-4"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00937.x"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdq071"},{"key":"e_1_2_9_34_1","first-page":"1037","article-title":"Strategies of hepatitis C screening in general practice. Results of a two\u2010center randomized trial","volume":"24","author":"Roudot\u2010Thoraval F","year":"2000","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2011.12.014"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X15585121"},{"key":"e_1_2_9_37_1","unstructured":"FossP. [The pharmaceutical industry view on health economics].2016. In Norwegian"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/11597660-000000000-00000"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022309"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.03932.x"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01927.x"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-S6-S2"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24656"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21176"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20836"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-14-440"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.004"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.006"},{"key":"e_1_2_9_49_1","volume-title":"What Benefit, for Whom and at What Cost?","author":"Melberg HO","year":"2003"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16686559"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X18754513"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12904","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T16:06:03Z","timestamp":1694880363000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/jvh.12904"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12904","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,16]]},"assertion":[{"value":"2017-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}